Global Ankylosing Spondylitis Medication 麻豆原创 Research Report 2024

Publication ID:

PB504241939

Publication Date:

April 8, 2024

Pages:

115

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

Ankylosing Spondylitis Medication is a drug used to relieve or treat ankylosing spondylitis.
The global Ankylosing Spondylitis Medication market was valued at US$ 6000 million in 2023 and is anticipated to reach US$ 10280 million by 2030, witnessing a CAGR of 9.0% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Ankylosing Spondylitis Medication, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Ankylosing Spondylitis Medication.
Report Scope
The Ankylosing Spondylitis Medication market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Ankylosing Spondylitis Medication market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Ankylosing Spondylitis Medication manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
麻豆原创 Segmentation
By Company
Pfizer
UCB Biopharma
Hetero Biopharma
Amgen
Cadila Pharmaceuticals
Torrent Pharmaceuticals
Cipla
Emcure Pharmaceuticals
Boehringer Ingelheim
Zhejiang Hisun Pharmaceuticals
Biocad
AbbVie
Mycenax Biotech
Celltrion
Gilead Sciences
Jiangsu HengRui Medicine Co., Ltd.
Izana Bioscience
Suzhou Zelgen Biopharmaceuticals
Iltoo Pharma
Kinevant Sciences
Qyuns Therapeutics
Akeso Biopharma
Nimbus Therapeutics
Enzene Biosciences
Xbrane Biopharma
Dice molecules
MSD
Segment by Type
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
Corticosteroids
Disease-Modifying Antirheumatic Drugs (DMARDs)
Biologics (TNF-blocking Agents)
Sulfasalazine
Methotrexate
Others
Segment by Application
Hospital
Specialist Clinic
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Ankylosing Spondylitis Medication manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Ankylosing Spondylitis Medication in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Ankylosing Spondylitis Medication 麻豆原创 Overview
1.1 Product Overview and Scope of Ankylosing Spondylitis Medication
1.2 Ankylosing Spondylitis Medication Segment by Type
1.2.1 Global Ankylosing Spondylitis Medication 麻豆原创 Value Comparison by Type (2024-2030)
1.2.2 Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
1.2.3 Corticosteroids
1.2.4 Disease-Modifying Antirheumatic Drugs (DMARDs)
1.2.5 Biologics (TNF-blocking Agents)
1.2.6 Sulfasalazine
1.2.7 Methotrexate
1.2.8 Others
1.3 Ankylosing Spondylitis Medication Segment by Application
1.3.1 Global Ankylosing Spondylitis Medication 麻豆原创 Value by Application: (2024-2030)
1.3.2 Hospital
1.3.3 Specialist Clinic
1.4 Global Ankylosing Spondylitis Medication 麻豆原创 Size Estimates and Forecasts
1.4.1 Global Ankylosing Spondylitis Medication Revenue 2019-2030
1.4.2 Global Ankylosing Spondylitis Medication Sales 2019-2030
1.4.3 Global Ankylosing Spondylitis Medication 麻豆原创 Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Ankylosing Spondylitis Medication 麻豆原创 Competition by Manufacturers
2.1 Global Ankylosing Spondylitis Medication Sales 麻豆原创 Share by Manufacturers (2019-2024)
2.2 Global Ankylosing Spondylitis Medication Revenue 麻豆原创 Share by Manufacturers (2019-2024)
2.3 Global Ankylosing Spondylitis Medication Average Price by Manufacturers (2019-2024)
2.4 Global Ankylosing Spondylitis Medication Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Ankylosing Spondylitis Medication, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Ankylosing Spondylitis Medication, Product Type & Application
2.7 Ankylosing Spondylitis Medication 麻豆原创 Competitive Situation and Trends
2.7.1 Ankylosing Spondylitis Medication 麻豆原创 Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Ankylosing Spondylitis Medication Players 麻豆原创 Share by Revenue
2.7.3 Global Ankylosing Spondylitis Medication 麻豆原创 Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Ankylosing Spondylitis Medication Retrospective 麻豆原创 Scenario by Region
3.1 Global Ankylosing Spondylitis Medication 麻豆原创 Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Ankylosing Spondylitis Medication Global Ankylosing Spondylitis Medication Sales by Region: 2019-2030
3.2.1 Global Ankylosing Spondylitis Medication Sales by Region: 2019-2024
3.2.2 Global Ankylosing Spondylitis Medication Sales by Region: 2025-2030
3.3 Global Ankylosing Spondylitis Medication Global Ankylosing Spondylitis Medication Revenue by Region: 2019-2030
3.3.1 Global Ankylosing Spondylitis Medication Revenue by Region: 2019-2024
3.3.2 Global Ankylosing Spondylitis Medication Revenue by Region: 2025-2030
3.4 North America Ankylosing Spondylitis Medication 麻豆原创 Facts & Figures by Country
3.4.1 North America Ankylosing Spondylitis Medication 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Ankylosing Spondylitis Medication Sales by Country (2019-2030)
3.4.3 North America Ankylosing Spondylitis Medication Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe Ankylosing Spondylitis Medication 麻豆原创 Facts & Figures by Country
3.5.1 Europe Ankylosing Spondylitis Medication 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Ankylosing Spondylitis Medication Sales by Country (2019-2030)
3.5.3 Europe Ankylosing Spondylitis Medication Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Ankylosing Spondylitis Medication 麻豆原创 Facts & Figures by Country
3.6.1 Asia Pacific Ankylosing Spondylitis Medication 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Ankylosing Spondylitis Medication Sales by Country (2019-2030)
3.6.3 Asia Pacific Ankylosing Spondylitis Medication Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Ankylosing Spondylitis Medication 麻豆原创 Facts & Figures by Country
3.7.1 Latin America Ankylosing Spondylitis Medication 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Ankylosing Spondylitis Medication Sales by Country (2019-2030)
3.7.3 Latin America Ankylosing Spondylitis Medication Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Ankylosing Spondylitis Medication 麻豆原创 Facts & Figures by Country
3.8.1 Middle East and Africa Ankylosing Spondylitis Medication 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Ankylosing Spondylitis Medication Sales by Country (2019-2030)
3.8.3 Middle East and Africa Ankylosing Spondylitis Medication Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Ankylosing Spondylitis Medication Sales by Type (2019-2030)
4.1.1 Global Ankylosing Spondylitis Medication Sales by Type (2019-2024)
4.1.2 Global Ankylosing Spondylitis Medication Sales by Type (2025-2030)
4.1.3 Global Ankylosing Spondylitis Medication Sales 麻豆原创 Share by Type (2019-2030)
4.2 Global Ankylosing Spondylitis Medication Revenue by Type (2019-2030)
4.2.1 Global Ankylosing Spondylitis Medication Revenue by Type (2019-2024)
4.2.2 Global Ankylosing Spondylitis Medication Revenue by Type (2025-2030)
4.2.3 Global Ankylosing Spondylitis Medication Revenue 麻豆原创 Share by Type (2019-2030)
4.3 Global Ankylosing Spondylitis Medication Price by Type (2019-2030)
5 Segment by Application
5.1 Global Ankylosing Spondylitis Medication Sales by Application (2019-2030)
5.1.1 Global Ankylosing Spondylitis Medication Sales by Application (2019-2024)
5.1.2 Global Ankylosing Spondylitis Medication Sales by Application (2025-2030)
5.1.3 Global Ankylosing Spondylitis Medication Sales 麻豆原创 Share by Application (2019-2030)
5.2 Global Ankylosing Spondylitis Medication Revenue by Application (2019-2030)
5.2.1 Global Ankylosing Spondylitis Medication Revenue by Application (2019-2024)
5.2.2 Global Ankylosing Spondylitis Medication Revenue by Application (2025-2030)
5.2.3 Global Ankylosing Spondylitis Medication Revenue 麻豆原创 Share by Application (2019-2030)
5.3 Global Ankylosing Spondylitis Medication Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Pfizer
6.1.1 Pfizer Corporation Information
6.1.2 Pfizer Description and Business Overview
6.1.3 Pfizer Ankylosing Spondylitis Medication Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Pfizer Ankylosing Spondylitis Medication Product Portfolio
6.1.5 Pfizer Recent Developments/Updates
6.2 UCB Biopharma
6.2.1 UCB Biopharma Corporation Information
6.2.2 UCB Biopharma Description and Business Overview
6.2.3 UCB Biopharma Ankylosing Spondylitis Medication Sales, Revenue and Gross Margin (2019-2024)
6.2.4 UCB Biopharma Ankylosing Spondylitis Medication Product Portfolio
6.2.5 UCB Biopharma Recent Developments/Updates
6.3 Hetero Biopharma
6.3.1 Hetero Biopharma Corporation Information
6.3.2 Hetero Biopharma Description and Business Overview
6.3.3 Hetero Biopharma Ankylosing Spondylitis Medication Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Hetero Biopharma Ankylosing Spondylitis Medication Product Portfolio
6.3.5 Hetero Biopharma Recent Developments/Updates
6.4 Amgen
6.4.1 Amgen Corporation Information
6.4.2 Amgen Description and Business Overview
6.4.3 Amgen Ankylosing Spondylitis Medication Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Amgen Ankylosing Spondylitis Medication Product Portfolio
6.4.5 Amgen Recent Developments/Updates
6.5 Cadila Pharmaceuticals
6.5.1 Cadila Pharmaceuticals Corporation Information
6.5.2 Cadila Pharmaceuticals Description and Business Overview
6.5.3 Cadila Pharmaceuticals Ankylosing Spondylitis Medication Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Cadila Pharmaceuticals Ankylosing Spondylitis Medication Product Portfolio
6.5.5 Cadila Pharmaceuticals Recent Developments/Updates
6.6 Torrent Pharmaceuticals
6.6.1 Torrent Pharmaceuticals Corporation Information
6.6.2 Torrent Pharmaceuticals Description and Business Overview
6.6.3 Torrent Pharmaceuticals Ankylosing Spondylitis Medication Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Torrent Pharmaceuticals Ankylosing Spondylitis Medication Product Portfolio
6.6.5 Torrent Pharmaceuticals Recent Developments/Updates
6.7 Cipla
6.6.1 Cipla Corporation Information
6.6.2 Cipla Description and Business Overview
6.6.3 Cipla Ankylosing Spondylitis Medication Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Cipla Ankylosing Spondylitis Medication Product Portfolio
6.7.5 Cipla Recent Developments/Updates
6.8 Emcure Pharmaceuticals
6.8.1 Emcure Pharmaceuticals Corporation Information
6.8.2 Emcure Pharmaceuticals Description and Business Overview
6.8.3 Emcure Pharmaceuticals Ankylosing Spondylitis Medication Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Emcure Pharmaceuticals Ankylosing Spondylitis Medication Product Portfolio
6.8.5 Emcure Pharmaceuticals Recent Developments/Updates
6.9 Boehringer Ingelheim
6.9.1 Boehringer Ingelheim Corporation Information
6.9.2 Boehringer Ingelheim Description and Business Overview
6.9.3 Boehringer Ingelheim Ankylosing Spondylitis Medication Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Boehringer Ingelheim Ankylosing Spondylitis Medication Product Portfolio
6.9.5 Boehringer Ingelheim Recent Developments/Updates
6.10 Zhejiang Hisun Pharmaceuticals
6.10.1 Zhejiang Hisun Pharmaceuticals Corporation Information
6.10.2 Zhejiang Hisun Pharmaceuticals Description and Business Overview
6.10.3 Zhejiang Hisun Pharmaceuticals Ankylosing Spondylitis Medication Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Zhejiang Hisun Pharmaceuticals Ankylosing Spondylitis Medication Product Portfolio
6.10.5 Zhejiang Hisun Pharmaceuticals Recent Developments/Updates
6.11 Biocad
6.11.1 Biocad Corporation Information
6.11.2 Biocad Ankylosing Spondylitis Medication Description and Business Overview
6.11.3 Biocad Ankylosing Spondylitis Medication Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Biocad Ankylosing Spondylitis Medication Product Portfolio
6.11.5 Biocad Recent Developments/Updates
6.12 AbbVie
6.12.1 AbbVie Corporation Information
6.12.2 AbbVie Ankylosing Spondylitis Medication Description and Business Overview
6.12.3 AbbVie Ankylosing Spondylitis Medication Sales, Revenue and Gross Margin (2019-2024)
6.12.4 AbbVie Ankylosing Spondylitis Medication Product Portfolio
6.12.5 AbbVie Recent Developments/Updates
6.13 Mycenax Biotech
6.13.1 Mycenax Biotech Corporation Information
6.13.2 Mycenax Biotech Ankylosing Spondylitis Medication Description and Business Overview
6.13.3 Mycenax Biotech Ankylosing Spondylitis Medication Sales, Revenue and Gross Margin (2019-2024)
6.13.4 Mycenax Biotech Ankylosing Spondylitis Medication Product Portfolio
6.13.5 Mycenax Biotech Recent Developments/Updates
6.14 Celltrion
6.14.1 Celltrion Corporation Information
6.14.2 Celltrion Ankylosing Spondylitis Medication Description and Business Overview
6.14.3 Celltrion Ankylosing Spondylitis Medication Sales, Revenue and Gross Margin (2019-2024)
6.14.4 Celltrion Ankylosing Spondylitis Medication Product Portfolio
6.14.5 Celltrion Recent Developments/Updates
6.15 Gilead Sciences
6.15.1 Gilead Sciences Corporation Information
6.15.2 Gilead Sciences Ankylosing Spondylitis Medication Description and Business Overview
6.15.3 Gilead Sciences Ankylosing Spondylitis Medication Sales, Revenue and Gross Margin (2019-2024)
6.15.4 Gilead Sciences Ankylosing Spondylitis Medication Product Portfolio
6.15.5 Gilead Sciences Recent Developments/Updates
6.16 Jiangsu HengRui Medicine Co., Ltd.
6.16.1 Jiangsu HengRui Medicine Co., Ltd. Corporation Information
6.16.2 Jiangsu HengRui Medicine Co., Ltd. Ankylosing Spondylitis Medication Description and Business Overview
6.16.3 Jiangsu HengRui Medicine Co., Ltd. Ankylosing Spondylitis Medication Sales, Revenue and Gross Margin (2019-2024)
6.16.4 Jiangsu HengRui Medicine Co., Ltd. Ankylosing Spondylitis Medication Product Portfolio
6.16.5 Jiangsu HengRui Medicine Co., Ltd. Recent Developments/Updates
6.17 Izana Bioscience
6.17.1 Izana Bioscience Corporation Information
6.17.2 Izana Bioscience Ankylosing Spondylitis Medication Description and Business Overview
6.17.3 Izana Bioscience Ankylosing Spondylitis Medication Sales, Revenue and Gross Margin (2019-2024)
6.17.4 Izana Bioscience Ankylosing Spondylitis Medication Product Portfolio
6.17.5 Izana Bioscience Recent Developments/Updates
6.18 Suzhou Zelgen Biopharmaceuticals
6.18.1 Suzhou Zelgen Biopharmaceuticals Corporation Information
6.18.2 Suzhou Zelgen Biopharmaceuticals Ankylosing Spondylitis Medication Description and Business Overview
6.18.3 Suzhou Zelgen Biopharmaceuticals Ankylosing Spondylitis Medication Sales, Revenue and Gross Margin (2019-2024)
6.18.4 Suzhou Zelgen Biopharmaceuticals Ankylosing Spondylitis Medication Product Portfolio
6.18.5 Suzhou Zelgen Biopharmaceuticals Recent Developments/Updates
6.19 Iltoo Pharma
6.19.1 Iltoo Pharma Corporation Information
6.19.2 Iltoo Pharma Ankylosing Spondylitis Medication Description and Business Overview
6.19.3 Iltoo Pharma Ankylosing Spondylitis Medication Sales, Revenue and Gross Margin (2019-2024)
6.19.4 Iltoo Pharma Ankylosing Spondylitis Medication Product Portfolio
6.19.5 Iltoo Pharma Recent Developments/Updates
6.20 Kinevant Sciences
6.20.1 Kinevant Sciences Corporation Information
6.20.2 Kinevant Sciences Ankylosing Spondylitis Medication Description and Business Overview
6.20.3 Kinevant Sciences Ankylosing Spondylitis Medication Sales, Revenue and Gross Margin (2019-2024)
6.20.4 Kinevant Sciences Ankylosing Spondylitis Medication Product Portfolio
6.20.5 Kinevant Sciences Recent Developments/Updates
6.21 Qyuns Therapeutics
6.21.1 Qyuns Therapeutics Corporation Information
6.21.2 Qyuns Therapeutics Ankylosing Spondylitis Medication Description and Business Overview
6.21.3 Qyuns Therapeutics Ankylosing Spondylitis Medication Sales, Revenue and Gross Margin (2019-2024)
6.21.4 Qyuns Therapeutics Ankylosing Spondylitis Medication Product Portfolio
6.21.5 Qyuns Therapeutics Recent Developments/Updates
6.22 Akeso Biopharma
6.22.1 Akeso Biopharma Corporation Information
6.22.2 Akeso Biopharma Ankylosing Spondylitis Medication Description and Business Overview
6.22.3 Akeso Biopharma Ankylosing Spondylitis Medication Sales, Revenue and Gross Margin (2019-2024)
6.22.4 Akeso Biopharma Ankylosing Spondylitis Medication Product Portfolio
6.22.5 Akeso Biopharma Recent Developments/Updates
6.23 Nimbus Therapeutics
6.23.1 Nimbus Therapeutics Corporation Information
6.23.2 Nimbus Therapeutics Ankylosing Spondylitis Medication Description and Business Overview
6.23.3 Nimbus Therapeutics Ankylosing Spondylitis Medication Sales, Revenue and Gross Margin (2019-2024)
6.23.4 Nimbus Therapeutics Ankylosing Spondylitis Medication Product Portfolio
6.23.5 Nimbus Therapeutics Recent Developments/Updates
6.24 Enzene Biosciences
6.24.1 Enzene Biosciences Corporation Information
6.24.2 Enzene Biosciences Ankylosing Spondylitis Medication Description and Business Overview
6.24.3 Enzene Biosciences Ankylosing Spondylitis Medication Sales, Revenue and Gross Margin (2019-2024)
6.24.4 Enzene Biosciences Ankylosing Spondylitis Medication Product Portfolio
6.24.5 Enzene Biosciences Recent Developments/Updates
6.25 Xbrane Biopharma
6.25.1 Xbrane Biopharma Corporation Information
6.25.2 Xbrane Biopharma Ankylosing Spondylitis Medication Description and Business Overview
6.25.3 Xbrane Biopharma Ankylosing Spondylitis Medication Sales, Revenue and Gross Margin (2019-2024)
6.25.4 Xbrane Biopharma Ankylosing Spondylitis Medication Product Portfolio
6.25.5 Xbrane Biopharma Recent Developments/Updates
6.26 Dice molecules
6.26.1 Dice molecules Corporation Information
6.26.2 Dice molecules Ankylosing Spondylitis Medication Description and Business Overview
6.26.3 Dice molecules Ankylosing Spondylitis Medication Sales, Revenue and Gross Margin (2019-2024)
6.26.4 Dice molecules Ankylosing Spondylitis Medication Product Portfolio
6.26.5 Dice molecules Recent Developments/Updates
6.27 MSD
6.27.1 MSD Corporation Information
6.27.2 MSD Ankylosing Spondylitis Medication Description and Business Overview
6.27.3 MSD Ankylosing Spondylitis Medication Sales, Revenue and Gross Margin (2019-2024)
6.27.4 MSD Ankylosing Spondylitis Medication Product Portfolio
6.27.5 MSD Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Ankylosing Spondylitis Medication Industry Chain Analysis
7.2 Ankylosing Spondylitis Medication Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Ankylosing Spondylitis Medication Production Mode & Process
7.4 Ankylosing Spondylitis Medication Sales and 麻豆原创ing
7.4.1 Ankylosing Spondylitis Medication Sales Channels
7.4.2 Ankylosing Spondylitis Medication Distributors
7.5 Ankylosing Spondylitis Medication Customers
8 Ankylosing Spondylitis Medication 麻豆原创 Dynamics
8.1 Ankylosing Spondylitis Medication Industry Trends
8.2 Ankylosing Spondylitis Medication 麻豆原创 Drivers
8.3 Ankylosing Spondylitis Medication 麻豆原创 Challenges
8.4 Ankylosing Spondylitis Medication 麻豆原创 Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 麻豆原创 Size Estimation
10.1.3 麻豆原创 Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

Companies Mentioned:

Pfizer
UCB Biopharma
Hetero Biopharma
Amgen
Cadila Pharmaceuticals
Torrent Pharmaceuticals
Cipla
Emcure Pharmaceuticals
Boehringer Ingelheim
Zhejiang Hisun Pharmaceuticals
Biocad
AbbVie
Mycenax Biotech
Celltrion
Gilead Sciences
Jiangsu HengRui Medicine Co., Ltd.
Izana Bioscience
Suzhou Zelgen Biopharmaceuticals
Iltoo Pharma
Kinevant Sciences
Qyuns Therapeutics
Akeso Biopharma
Nimbus Therapeutics
Enzene Biosciences
Xbrane Biopharma
Dice molecules
MSD

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.